A study evaluating lenalidomide as a first line therapy followed by hypomethylating agents as second line therapy and vice versa in non-del5q lower-risk myelodysplastic syndrome patients.

Trial Profile

A study evaluating lenalidomide as a first line therapy followed by hypomethylating agents as second line therapy and vice versa in non-del5q lower-risk myelodysplastic syndrome patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jan 2017 New trial record
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top